LifeMD, Inc. (LFMD) Income Statement
LFMD 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsLFMD revenue and net income
Where LFMD's revenue goes
2025Each bar shows an amount and its share of revenue. LFMD kept −3.7% of revenue as net income.
LFMD profit margins
LFMD growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −8.7% | +17.7% | +39.1% | +66.0% |
| Gross profit | −17.8% | +15.5% | +40.4% | +66.1% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | −140.5% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LFMD quarterly EPS vs estimates
LifeMD beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 16, 2026 (estimate $-0.14).
LFMD income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $194.1M | $212.5M | $152.5M | $119.0M | $92.9M | $37.3M | $12.5M | $8.3M | $5.1M | $5.2M |
| Cost of revenue | $39.3M | $24.1M | $18.9M | $18.7M | $18.0M | $8.9M | $2.5M | $2.0M | $1.5M | $1.9M |
| Gross profit | $154.8M | $188.4M | $133.6M | $100.4M | $74.9M | $28.4M | $9.9M | $6.4M | $3.6M | $3.3M |
| Research & development | $7.3M | $9.5M | $6.1M | $3.0M | $948,157 | $446,749 | $222,877 | $120,541 | — | — |
| Sales, general & admin | $144.0M | $175.7M | $128.1M | $125.3M | $122.1M | $83.9M | $11.3M | $8.4M | $4.6M | $4.5M |
| Total operating expenses | $162.4M | $204.5M | $148.1M | $143.8M | $129.2M | $86.2M | $12.8M | $8.4M | $4.6M | $4.5M |
| Operating income | −$7.7M | −$16.1M | −$14.5M | −$43.4M | −$54.3M | −$57.8M | −$2.9M | −$2.1M | −$1.1M | −$1.2M |
| Interest expense | $1.4M | $2.2M | $2.6M | $1.3M | $3.0M | $1.7M | $761,150 | $354,388 | $100,523 | $48,611 |
| Income before taxes | −$10.2M | −$18.3M | −$17.4M | −$44.7M | −$61.3M | −$60.4M | −$3.7M | −$1.5M | −$1.2M | −$1.2M |
| Income taxes | $45,721 | $402,000 | $428,000 | $360,700 | $7,700 | $122,500 | −$122,500 | −$124,700 | −$12,488 | −$115,749 |
| Net income | −$7.1M | −$18.9M | −$20.6M | −$45.5M | −$60.9M | −$60.5M | −$3.1M | −$1.2M | −$1.2M | −$1.1M |
| EBITDA | −$1.5M | −$6.7M | −$8.2M | −$35.9M | −$57.9M | −$57.4M | −$2.6M | −$1.9M | −$1.1M | −$1.2M |
| EPS (diluted) | −$0.15 | $0.37 | −$0.14 | −$1.11 | −$1.64 | −$6.35 | −$0.32 | −$0.14 | −$0.16 | −$0.16 |
| Gross margin | 79.8% | 88.7% | 87.6% | 84.3% | 80.6% | 76.1% | 79.7% | 76.3% | 70.6% | 62.9% |
| Operating margin | −4.0% | −7.6% | −9.5% | −36.5% | −58.5% | −155.0% | −23.2% | −24.7% | −21.1% | −22.4% |
| Net margin | −3.7% | −8.9% | −13.5% | −38.3% | −65.6% | −162.3% | −25.2% | −14.9% | −23.9% | −21.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $47.3M | $50.2M | $46.9M | $60.2M | $62.2M | $65.7M | $64.3M | $53.3M | $50.7M | $44.1M | $44.9M | $38.6M |
| Cost of revenue | $5.3M | $7.6M | $8.5M | $7.4M | $7.4M | $8.6M | $9.4M | $5.0M | $5.0M | $4.6M | $5.4M | $4.8M |
| Gross profit | $42.0M | $42.6M | $38.3M | $52.8M | $54.8M | $57.1M | $54.8M | $48.3M | $45.6M | $39.5M | $39.5M | $33.8M |
| Research & development | $1.8M | $121,211 | $1.8M | $2.8M | $2.7M | $2.7M | $2.4M | $2.6M | $2.4M | $2.1M | $2.0M | $1.5M |
| Sales, general & admin | $41.7M | $45.1M | $34.6M | $46.1M | $46.7M | $46.2M | $45.8M | $44.7M | $44.9M | $39.5M | $36.0M | $33.2M |
| Total operating expenses | $49.1M | $51.5M | $39.4M | $54.7M | $55.7M | $54.5M | $53.8M | $52.3M | $51.9M | $45.7M | $41.7M | $38.4M |
| Operating income | −$7.1M | −$8.9M | −$1.1M | −$2.0M | −$906,772 | $2.5M | $1.0M | −$4.0M | −$6.3M | −$6.2M | −$2.2M | −$4.6M |
| Interest expense | $45,660 | $56,476 | $190,791 | $262,456 | $663,027 | $626,275 | $614,074 | $558,597 | $531,468 | $477,678 | $622,685 | $713,766 |
| Income before taxes | −$7.1M | −$8.9M | −$1.1M | −$3.4M | −$1.6M | $1.9M | $404,168 | −$4.6M | −$6.8M | −$6.6M | −$2.8M | −$5.3M |
| Income taxes | — | $776,563 | $13,898 | $169,134 | — | — | $169,477 | $232,523 | $38,601 | $119,437 | $428,000 | −$6.0M |
| Net income | −$7.1M | −$8.9M | −$1.5M | −$3.8M | −$2.1M | $1.4M | −$106,272 | −$4.7M | −$6.9M | −$6.8M | −$3.7M | −$6.1M |
| EBITDA | −$5.0M | −$6.9M | $876,088 | −$133,334 | $1.9M | $5.2M | $3.6M | −$1.4M | −$4.0M | −$4.1M | −$1.9M | −$2.8M |
| EPS (diluted) | −$0.16 | −$0.15 | $0.06 | −$0.08 | −$0.01 | $0.03 | $0.21 | $0.09 | $0.06 | $0.01 | −$0.12 | $0.08 |
| Gross margin | 88.8% | 84.8% | 81.8% | 87.7% | 88.1% | 86.8% | 85.3% | 90.6% | 90.1% | 89.6% | 88.1% | 87.6% |
| Operating margin | −15.1% | −17.8% | −2.3% | −3.3% | −1.5% | 3.9% | 1.6% | −7.5% | −12.4% | −14.0% | −4.8% | −11.8% |
| Net margin | −15.0% | −17.7% | −3.2% | −6.3% | −3.3% | 2.1% | −0.2% | −8.7% | −13.6% | −15.3% | −8.3% | −15.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LFMD's financial statements (latest annual report filed March 10, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LFMD financial results
In fiscal year 2025 (ended December 31, 2025), LifeMD reported revenue of $194.1 million, down 8.7% from the year before. It had a net loss of $7.1 million, a net profit margin of −3.7%. Diluted earnings per share came to −$0.15. Over five years revenue grew at an average rate of 39.1% a year.
See the LFMD stock overview for the latest quote and news, or the LFMD chart for price history and technical indicators.
LFMD income statement FAQ
What is LifeMD's annual revenue?
LifeMD reported total revenue of $194.1 million for fiscal year 2025, which ended on December 31, 2025. That was down 8.7% from $212.5 million the previous year.
Is LifeMD profitable?
No. LifeMD reported a net loss of $7.1 million in fiscal 2025, a net profit margin of −3.7%; its operating margin was −4.0%.
What is LifeMD's gross margin?
LifeMD's gross margin was 79.8% in fiscal 2025: for every $100 of revenue, LifeMD kept $80 after the direct cost of its products and services.
How much does LifeMD spend on research and development?
LifeMD spent $7.3 million on research and development in fiscal 2025, 3.8% of revenue.
How fast is LifeMD growing?
Revenue grew 39.1% a year on average over the last five fiscal years, from $37.3 million to $194.1 million.
What are LifeMD's earnings per share?
LifeMD earned $-0.15 per diluted share in fiscal 2025, compared with $0.37 a year earlier.
When will LifeMD report its next earnings?
LifeMD is expected to report results for the quarter ending September 30, 2026 on November 16, 2026.
When does LifeMD's fiscal year end?
LifeMD's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 10, 2026.